From Hanson Wade Group - 4th Ophthalmic Drug Delivery Summit Dec 5 2025 Ripple Therapeutics, a clinical-stage company developing polymer-free sustained release drug delivery systems, has entered into an evaluation and licensing option agreement with an affiliate of Bausch + Lomb. Advancing polymer-free controlled drug delivery Ripple’s proprietary technology platform is based on the discovery that drugs can be chemically engineered into controlled-release prodrugs without relying on polymers, a